- Home
- GDOT vs MREO Comparison
GDOT vs MREO Comparison
Compare GDOT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDOT
- MREO
- Stock Information
- Founded
- GDOT 1999
- MREO 2015
- Country
- GDOT United States
- MREO United Kingdom
- Employees
- GDOT N/A
- MREO N/A
- Industry
- GDOT Finance: Consumer Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- GDOT Finance
- MREO Health Care
- Exchange
- GDOT Nasdaq
- MREO Nasdaq
- Market Cap
- GDOT 363.9M
- MREO 369.2M
- IPO Year
- GDOT 2010
- MREO N/A
- Fundamental
- Price
- GDOT $8.36
- MREO $2.30
- Analyst Decision
- GDOT Hold
- MREO Strong Buy
- Analyst Count
- GDOT 3
- MREO 7
- Target Price
- GDOT $9.33
- MREO $7.71
- AVG Volume (30 Days)
- GDOT 1.8M
- MREO 1.2M
- Earning Date
- GDOT 05-08-2025
- MREO 03-26-2025
- Dividend Yield
- GDOT N/A
- MREO N/A
- EPS Growth
- GDOT N/A
- MREO N/A
- EPS
- GDOT N/A
- MREO N/A
- Revenue
- GDOT $1,718,370,000.00
- MREO N/A
- Revenue This Year
- GDOT $11.62
- MREO N/A
- Revenue Next Year
- GDOT $13.35
- MREO $69.09
- P/E Ratio
- GDOT N/A
- MREO N/A
- Revenue Growth
- GDOT 14.69
- MREO N/A
- 52 Week Low
- GDOT $6.12
- MREO $2.23
- 52 Week High
- GDOT $13.58
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- GDOT 56.21
- MREO 36.53
- Support Level
- GDOT $7.03
- MREO $2.23
- Resistance Level
- GDOT $8.60
- MREO $2.73
- Average True Range (ATR)
- GDOT 0.45
- MREO 0.14
- MACD
- GDOT 0.21
- MREO -0.00
- Stochastic Oscillator
- GDOT 90.32
- MREO 14.85
About GDOT Green Dot Corporation $0.001 par value
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).